Novo Nordisk Pharmatech

Sustainability Report and Carbon Intensity Rankings

Is Novo Nordisk Pharmatech doing their part?

Their DitchCarbon score is 69

Novo Nordisk Pharmatech has a DitchCarbon Score of 69, indicating a moderate level of sustainability in their operations. This score reflects the company’s efforts to manage and reduce its carbon intensity. A higher score would signify even greater success in minimizing their environmental impact through lower carbon emissions.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

Novo Nordisk Pharmatech is part of the industrial manufacturing sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Medium

High

Very high

Novo Nordisk Pharmatech operates in Denmark, a country with a very low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing the carbon footprint associated with their operations.
27.71%

...this company is doing 27.71% better in emissions than the industry average.

Novo Nordisk Pharmatech, founded in 1949 and acquired by Novo Nordisk in 1986, operates from Køge in the industrial manufacturing sector. As a prominent supplier, the company offers high-quality ingredients for the biopharmaceutical and pharmaceutical industries, including recombinant insulin and quaternary ammonium compounds. They are committed to excellence in manufacturing, quality control, and supply chain management, ensuring reliable product delivery to healthcare facilities and patients worldwide.

Good news, Novo Nordisk Pharmatech has embraced SBTi commitments

Novo Nordisk Pharmatech has established targets to significantly reduce their greenhouse gas emissions from company operations, which include both direct emissions and indirect emissions from purchased energy. These targets align with the ambitious goal of limiting global warming to 1.5°C, reflecting a strong commitment to environmental sustainability.

There’s always room for improvement,

DitchCarbon recommends...

Novo Nordisk Pharmatech should set clear, science-driven targets for reducing their Scope 3 emissions and consistently report on their progress while promoting sustainable practices throughout their supply chain.
Participating

Meet our 360 emissions intelligence platform

✓ Comprehensive database of calculators, life cycle analysis, carbon footprints of companies

✓ Peer group, recommended actions, historical reports, data sources

✓ Complete Scope 1-2-3 data, emission factors, yearly breakdown

✓ Complete SBTi and CDP status with sources

✓ Company emission source URLs

✓ Supply level emission factors

30+ emissions data points on millions of companies

✓ Comprehensive database of calculators, life cycle analysis, carbon footprints of companies

✓ Peer group, recommended actions, historical reports, data sources

✓ Complete Scope 1-2-3 data, emission factors, yearly breakdown

✓ Complete SBTi and CDP status with sources

✓ Company emission source URLs

✓ Supply level emission factors

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.